The development of vaccines that provide sterile protection against human malaria is a major global public health priority requiring a better understanding of the mechanisms involved in natural and vaccine-induced sterile immunity. RNAseq was used to profile gene expression of peripheral blood samples from 12 Duffy positive (Fy+) (Plasmodium vivax susceptible) volunteers enrolled in a phase 2 trial who were vaccinated with radiation attenuated P. vivax sporozoites (RAS; 5 were protected, 7 not) and from 5 Fy-(P. vivax resistant) volunteers exposed to mosquitoes harboring live non-attenuated 
3

AUTHOR SUMMARY:
Transcriptomic analysis has shed considerable light on the molecular mechanisms of vaccine efficacy against a variety of viral pathogens, but has not yet been used in relation to parasite vaccinology. Here we describe whole peripheral blood gene expression profiling to contrast the contributions of myeloid and lymphoid immune responses to vaccine-induced and natural protection against Plasmodium vivax- decrease and potentially eliminate malaria [1, 2] . Human malaria is caused by at least five different 4 parasite species of the genus Plasmodium, which display distinct biology and disease 5 manifestations. P. falciparum and P. vivax are the most relevant to public health worldwide [3] , 6 the latter accounting for ~20% of the global malaria burden and producing a chronic disease that 7 may develop to complicated and severe cases with infrequent lethality [4, 5] . 8 
9
Multiple genetic traits partially protect humans from severe clinical manifestations or 10 completely prevent blood parasite development [6] , thereby reducing disease in infected 11 individuals [7] . For example, lack of expression of the Duffy (Fy) blood group in African 12 populations associates with protection from P. vivax blood infection [8, 9] and consequently from 13 the clinical manifestations associated with this parasite stage, despite its full development in the 14 liver. This species also has the capacity to remain dormant as hypnozoites in the liver and 15 periodically reactivate, inducing clinical relapses which represent an enormous challenge for P. 16 vivax control and elimination and highlights the importance of developing vaccines targeting the 17 parasite liver forms. Rational design of malaria vaccines is likely to be accelerated by enhanced 18 understanding of the molecular mechanisms involved in the clinical immunity developed in 19 individuals permanently exposed to infection in endemic areas [10, 11] , or by sterile immunity 20 experimentally induced by vaccination with attenuated parasites [12] . 21 
22
In recent years, we have developed a controlled human malaria infection model with P. vivax 23 sporozoites (CHMI) in Colombia [13] [14] [15] , which supported gene expression profiling of the early 24 response to P. vivax in malaria-naïve and semi-immune volunteers [16] . More recently, a [20] [21] [22] [23] [24] [25] volunteer Phase I/II clinical trial of a P. vivax radiation-attenuated sporozoite (RAS) vaccine 26 assessed the protective efficacy against P. vivax sporozoite infectious challenge [17] . 27 
28
Systems biology approaches are being implemented to enhance the knowledge and 29 understanding of immunity acquisition to infectious agents [18, 19] , and gene expression profiling 30 has been used to gain insight into natural clinical protection to viral diseases [17, 20, 21] , as well as 31 for identifying gene signatures associated with vaccination response [22] [23] [24] [25] . However, while it is 32
clear that multiple arms of the immune system are engaged in this protection, the precise 33 mechanisms leading to immunity remain to be elucidated. In malaria, the pre-erythrocytic liver 34 parasite stage, is thought to be an optimal vaccine target because during this phase, the infection 35 remains clinically silent; once the parasite is released to the blood stream (erythrocytic stage) 36 malaria clinical manifestations develop. Gene expression profiling of leukocytes from humans 37 rendered immunologically sterile by RAS experimental vaccination is likely to provide valuable 38 insight for rational subunit vaccine development. 39 
40
This study focuses on transcriptomic profiles of human leukocytes to establish the nature of 41 differences in the immune profiles between: (i) Fy+ protected and non-protected by RAS 42 vaccination, and (ii) experimentally and naturally (Fy-) refractory individuals exposed to 43 immunization with non-attenuated sporozoites. Knowledge of the co-regulation of gene expression 44 6 in blood is used to partition the transcriptional profiles into contributions of various myeloid and 45 lymphoid cell-types. 46 
47
RESULTS
49
Peripheral blood gene expression profiles were obtained for 20 volunteers who completed a single 50 blind randomized clinical trial of RAS immunization [17] , as schematized in Fig 1. Five 51 individuals were Fy-, and 15 were Fy+ (12 RAS immunized and three mock-vaccination controls); 52 of the RAS group, 5 attained sterile immunity, 6 contracted malaria, and 1 was infected but 53 asymptomatic. Table 1 shows the demographics and clinical attributes of these volunteers. The 54 final RNAseq dataset includes Baseline, Pre-challenge and Diagnosis day time points with 55 exclusion of five samples as reported in S1 Table. It consists of 55 RNAseq single end 100bp  56 samples with a total of 13,282 genes that had at least one cpm in at least 3 of the samples. 57 58 Principal variance component analysis indicates that 11.6 % of the variation is between the 88 three DPS classes of individual (Duffy-negative, protected, susceptible), 12.7 % between the three 89 time points, and 3.3% attributable to an interaction effect between DPS status and time point. 90
Unusually for peripheral blood profiles, gender also shows a large effect (14.4%), but this is mostly 91 due to the association of gender with protection in the post-challenge samples as described below. 92
Age was not a significant source of variation. Post-hoc analysis indicated that the Diagnosis day 93 samples tend to be the most divergent, and that the susceptible (Fy+) [25, 28] and Blood Informative Transcript (BIT) [29] axes are 113 parallel methods for characterizing patterns of differential gene expression of conserved gene co-114 expression sets that report immune functions. The former represents coordinated gene expression 115 as over 250 modules each annotated with respect to some aspect of immune physiology, whereas 116 the latter collapses modules into eight larger axes of covariation. Two-way hierarchical clustering 117 analysis of PC1 of the BTMs and BIT axis data reveals 12 clusters of co-expressed modules (8 of 118 which include one BIT Axis), and three distinct clusters of individual (Fig 3) . These three clusters 119 Table) , and 49 modules that are associated with clinical 154 susceptibility, being elevated in the presence of parasites (S2b Table) . Examples of these modules the same direction. This is particularly notable for the T-cell genes (red), but is also true of the 176 neutrophil genes (blue) which are generally lower in Fy-individuals naturally refractory (Fig 5B) , 177 but this may also simply reflect a greater proportion of African ancestry in these individuals. 178
179
Despite this similarity between the responses of individuals protected against live parasite, 180 there are some very clear differences between the Fy-and Fy+ samples prior to the live sporozoite 181 challenge: 79 genes were significantly up-regulated at FDR 5% in Fy -, and 658 genes are down-182 regulated. This result confirms that Fy status, through its influence on the P. vivax parasite cycle 183 has a marked impact on the overall gene expression profile. It is likely that a different antigen 184 repertoire is presented to the immune system in the Fy+ volunteers as consequence of the limited 185 development of RAS as opposed to the full sporozoite development in the Fy-individuals. Fig 6  186 shows five examples of BTM that are differentially expressed in Fy-volunteers at pre-challenge. 187
These include elevated gene expression related to subsets of chemokine signaling, B cell 188 development, and integrin-mediated cell signaling, and down-regulation of extracellular matrix 189 and complement activation (suggesting reduced general inflammation at baseline). S3 Table  190 provides a full listing of Duffy genotype-biased gene expression modules. varied at diagnosis according to infection status (Fig 7A) , but these differences could not be 206 confirmed by transcriptional biomarkers of the sub-types defined in [31] . In whole blood, 207 there is covariance of the 27 biomarker genes (Fig 7B) such that their first three principal 208 components vary by time and infection (Fig 7C) , but the covariance does not correspond to 209 the patterns of the B-cell sub-types observed by flow cytometry analysis, so is presumably 210 due to expressed in other immune cell types. Alternatively, a role for plasma cells is 211 13 implicated by strong up-regulation of CD38 (Fig S1) and hundreds of co-expressed genes 212 that distinguish short-and long-lived plasma cells [32, 33] in the non-protected individuals 213 (Fig S2) . This suggests that they are specifically engaged in immunoglobulin-based clearance 214 of the parasite, but sub-type specific RNA-Seq would be required to confirm this hypothesis. 215
216
T cell activation and differentiation were also up-regulated only in protected 217 individuals, supporting previous findings that T cells proliferation is associated with P. 218 falciparum malaria protection in RTS,S-immunized volunteers [34, 35] , including enhanced 219 activation of memory T cells [36] . Other studies have also reported an increase in T cell 220 responses and a delayed pre-patent period after malaria challenge [37, 38] , although there is 221 some heterogeneity in lymphocyte activation levels. This may be due to a delay in the timing 222 rather than a dampening of the lymphocyte response, since 007 and 012 volunteers, with 223 lesser B-and T-cell gene activity also had specifically elevated activity of dozens of interferon 224 response-related modules. In contrast to the protected volunteers, the non-protected 225 Volunteer 026, who displayed parasitemia but was asymptomatic, had a hybrid profile 236 consisting of a strong interferon response and inflammatory activation, also with differences 237 in modules related to the cell cycle as observed previously in semi-immune individuals in 238 response to a P. vivax CHMI [16] . She also had a signature of platelet activation which was 239 recently proposed to have protective properties against malaria infection by binding 240 infected erythrocytes and killing the parasite specifically by factor 4 activity [40, 41] . Larger 241 studies should thus enable distinction between pathways that provide vaccine-mediated 242 sterile protection, and the ones that are more involved in malaria symptomology. In 243 addition, many immune events that occur locally in the liver would escape detection by 244 transcriptome profiling of peripheral blood cells. Notably, liver cells infected in vitro with 245 irradiated and non-irradiated P. falciparum display differential gene expression as a function of 246 sporozoite radiation status [42] . 247
248
By demonstrating differential systemic responses that correlate with clinical outcomes, 249 our study further supports the use of systems biology approaches to understand vaccine 250 efficacy. Follow-up experimental approaches might utilize ex vivo parasite challenges to 251 evaluate specific cellular contributions to immunity and protection, with a particular focus 252 on the reasons for the female-bias, which has also been seen in other settings [43, 44] . 253
Further, profiling of sorted cell types during vaccination and in the pre-patent period days 254 after initial infection should also reveal critical mechanisms of immunity. 255
256
MATERIALS AND METHODS 257
Clinical Study 259
This study is based on a single-blind clinical trial registered at ClinicalTrials.gov as NCT01082341 260 conducted in Colombia and described in [17] , which included healthy adult volunteers, males and case of the RAS vaccinees, mosquitoes harboring P. vivax mature sporozoites had been irradiated 272 whereas the Fy-volunteers were exposed to mosquitoes harboring live non-attenuated parasites 273 [17] . The mock-controls were immunized by exposure to the bite of non-infected mosquitoes. Two 274 weeks after the final vaccine dose, the "pre-challenge" blood sample was drawn, and six weeks 275 later, volunteers were challenged by exposure to the bites of 3-4 mosquitoes infected with live, 276 non-irradiated P. vivax sporozoites. Twelve or thirteen days later, at first diagnosis of infection in 277 susceptible volunteers, the final "Diagnosis" blood sample was taken, and when necessary curative 278 anti-malarial medication was given. Two of the mock-controls contracted malaria after challenge 279 with live parasites but one who accidentally received one round of vaccination remained 280 uninfected. Of the 12 RAS-vaccinated individuals, six (all women) were symptom-free, one of 281 whom nevertheless had parasites in her blood. The other six (five men, one woman) were not 282 protected and developed malaria. As expected, all five Fy-volunteers (all women) were protected 283 from blood infection. 284
285
B-cell phenotype analysis 286
Peripheral Blood Mononuclear Cells (PBMC) were isolated by ficoll-histopaque (Sigma-287 Aldrich, USA) density gradient according to the manufacturer's instructions. Briefly, fresh PBMC 288 were incubated with mouse mAbs specific for human B cell markers conjugated to fluorophores. 289
The monoclonal panel included: PerCP-CD19, PE-CD10, APC-Cy7-CD20, PerCy7-CD21, APC-290
CD27, and FITC-CD95 (BD Science, San Jose, CA). Isotype matched controls FITC-IgG (BD 291
Pharmigen, San Jose, CA) were used in all experiments. Samples were acquired using a 292 USA), which preserves whole blood RNA at -80°C indefinitely. Whole blood (predominantly 301 leukocyte) mRNA was extracted using Tempus Blood RNA Tube isolation kits following the 302 protocol provided by Applied Biosystems. Sample RNA quality was determined based on the 303 Agilent Bioanalyzer RNA Integrity score (RIN: S1 Table) . Two RNA samples, one from pre-304 challenge time of Fy+ control group and the other from diagnosis time of Fy-group, were severely 305 degraded and therefore not included for sequencing. A few samples had RIN <6, but these were 306 not found to be outliers in the analysis. 
Data analysis 316
The quality of raw RNAseq reads in Fastq files was evaluated using FastQC software. The overall 317 alignment rate was 93%, but three samples (B025, DGS006 and DGS065) failed QC and were 318 excluded. The 100 bp single-end reads were aligned to the human genome (hg19/GRCh37 319 assembly with the UCSC reference annotation) using Bowtie via Tophat2 [45] . Transcript 320 abundance was estimated at the level of the whole gene as counts per million-mapped-reads (cpm) 321 values using HTSeq [46] . Scale Trimmed Mean of the M-values (TMM) normalization was then 322 performed using edgeR from Bioconductor [47] , and differential expression was assessed using 323 the linear modeling framework for RNAseq data in edgeR, selecting transcripts significant at the 324 Benjamini-Hochberg false discovery rate of 10% (corresponding to a p-value of ~0.0001). were qualitatively the same as the TMM analysis, we only report the TMM. 334
335
Ancestry proportions of the study participants were inferred using ADMIXTURE [26] with 336 k=3 populations, based on common genotypes called with the GATK HaplotypeCaller in all three 337 samples of an individual [27] , merged with the vcfmerge utility in VCF Tools [49] , and matched 338 to the 1000 Genomes Project [50] variants with PLINK [51] . Red, blue, and olive colored circles 339 at the corners of the triangle are representative samples from the 1000 Genomes Project and green 340 circles are study participants. These tend to have higher African ancestry than the Medellin 341
Colombians from the 1000 Genomes Project represented by the purple circles. The five outliers 342 with greater than 40% African ancestry close to the left hand edge of the triangle in Fig 2 are networks from integrative analysis of >30,000 transcriptomes in 500 public studies [25] . These 349 . Axis 4 appears to be related to house-keeping, Axis 6 is as yet undefined, while a newly 359 identified Axis 10 first reported here is enriched for regulation of mitosis and cell division. These 360 axes are related to 28 modules of co-expressed genes described in [28] . 361
362
Both BTM and BIT Axes are computed as first principal components (PC1) of the co-363 regulated genes, either all of the genes in each module, or the 10 axis-defining BIT for each Axis 364 (almost identical scores are obtained with 5 or 20 transcripts [29] ). These scores were contrasted 365 with respect to the clinical status groups across the three time points, using standard parametric t-366 tests or analysis of variance. Two-way hierarchical clustering of the BTM and BIT scores was 367 used to assess the overall functional relatedness of samples and modules, using Ward's method 368 implemented in JMP Genomics. Analyses of the correlation of specific gene sets among groups 369
were performed with custom scripts in R, accessing datasets referenced in the text. A.
B.
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